Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Mellor AL, Munn DH: Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat. Rev. Immunol.8,74–80 (2008).
  Medline CASGoogle Scholar
• 2  Grohmann U, Fallarino F, Puccetti P: Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol.24,242–248 (2003).
  Medline CASGoogle Scholar
• 3  Mellor AL, Munn DH: IDO expression in dendritic cells: Tolerance and tryptophan catabolism. Nat. Rev. Immunol.4,762–774 (2004).
  Medline CASGoogle Scholar
• 4  Mellor AL, Munn DH: Immune privilege: a recurrent theme in immunoregulation? Immunol. Rev.213,5–11 (2006).
  Google Scholar
• 5  Munn DH, Mellor AL: Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest.117,1147–1154 (2007).
  Medline CASGoogle Scholar
• 6  Sugimoto H, Oda S, Otsuki T et al.: Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O₂ incorporation by a heme-containing dioxygenase. Proc. Natl Acad. Sci. USA103,2611–2616 (2006).
  Medline CASGoogle Scholar
• 7  Ball HJ, Sanchez-Perez A, Weiser S et al.: Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene396,203–213 (2007).
  Medline CASGoogle Scholar
• 8  Metz R, Duhadaway JB, Kamasani U et al.: Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res.67,7082–7087 (2007).
  Medline CASGoogle Scholar
• 9  Suzuki T, Yokouchi K, Kawamichi H et al.: Comparison of the sequences of Turbo and Sulculus indoleamine dioxygenase-like myoglobin genes. Gene308,89–94 (2003).
  Medline CASGoogle Scholar
• 10  Hayashi T, Beck L, Rossetto C et al.: Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J. Clin. Invest.114,270–279 (2004).
  Medline CASGoogle Scholar
• 11  Baban B, Chandler P, McCool D et al.: Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J. Reprod. Immunol.61,67–77 (2004).
  Medline CASGoogle Scholar
• 12  Odemuyiwa SO, Ghahary A, Li Y et al.: Cutting edge: human eosinophils regulate T cell subset selection through indoleamine 2,3-dioxygenase. J. Immunol.173,5909–5913 (2004).
  Medline CASGoogle Scholar
• 13  von Bubnoff D, Bausinger H, Matz H et al.: Human epidermal langerhans cells express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. J. Invest. Dermatol.123,298–304 (2004).
  Medline CASGoogle Scholar
• 14  Beutelspacher SC, Tan PH, McClure MO, Larkin DF, Lechler RI, George AJ: Expression of indoleamine 2,3-dioxygenase (IDO) by endothelial cells: implications for the control of alloresponses. Am. J. Transplant.6,1320–1330 (2006).
  Medline CASGoogle Scholar
• 15  Mohib K, Wang S, Guan Q et al.: Indoleamine 2,3-dioxygenase expression promotes renal ischemia-reperfusion injury. Am. J. Physiol. Renal Physiol.295,F226–34 (2008).
  Medline CASGoogle Scholar
• 16  Cook CH, Bickerstaff AA, Wang JJ et al.: Spontaneous renal allograft acceptance associated with ‘regulatory’ dendritic cells and IDO. J. Immunol.180,3103–3112 (2008).
  Medline CASGoogle Scholar
• 17  Littlejohn TK, Takikawa O, Truscott RJ, Walker MJ: Asp274 and his346 are essential for heme binding and catalytic function of human indoleamine 2,3-dioxygenase. J. Biol. Chem.278,29525–29531 (2003).
  Medline CASGoogle Scholar
• 18  Aitken JB, Thomas SE, Stocker R et al.: Determination of the nature of the heme environment in nitrosyl indoleamine 2,3-dioxygenase using multiple-scattering analyses of X-ray absorption fine structure. Biochemistry43,4892–4898 (2004).
  Medline CASGoogle Scholar
• 19  Romani L, Fallarino F, De Luca A et al.: Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature451,211–215 (2008).▪▪ Linked a genetic defect in NADPH oxidase activity with a biochemical defect in indoleamine 2,3-dioxygenase (IDO) functionality in a mouse model of chronic granulomatous disease. The innate defect in IDO led to increased IL-17 production and expansion of proinflammatory T cells, which increased susceptibility to Aspergillus fumigatus infection.
  Medline CASGoogle Scholar
• 20  Munn DH, Sharma MD, Hou D et al.: Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest.114,280–290 (2004).
  Medline CASGoogle Scholar
• 21  Gajewski TF: Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin. Cancer Res.13,5256–5261 (2007).
  Medline CASGoogle Scholar
• 22  Lee JR, Dalton RR, Messina JL et al.:Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab. Invest.83,1457–1466 (2003).
  Medline CASGoogle Scholar
• 23  Uyttenhove C, Pilotte L, Theate I et al.: Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med.9,1269–1274 (2003).▪ Directly linked murine tumor expression of IDO with tumor survival, and showed that pharmacologic IDO inhibition increased antitumor immunity in IDO-expressing tumors from preimmunized mice.
  Medline CASGoogle Scholar
• 24  Zheng X, Koropatnick J, Li M et al.: Reinstalling anti-tumor immunity by inhibiting tumor-derived immunosuppressive molecule indoleamine 2,3-dioxygenase through RNA interference. J. Immunol.177,5639–5646 (2006).
  Medline CASGoogle Scholar
• 25  Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC: Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med.11,312–319(2005).
  Medline CASGoogle Scholar
• 26  Hou D, Muller AJ, Sharma M et al.: Stereoisomers of 1-methyl-tryptophan as pharmacologic inhibitors of indoleamine 2,3-dioxygenase. Cancer Research67,792–801 (2007).
  Medline CASGoogle Scholar
• 27  Muller AJ, Sharma MD, Chandler PR et al.: Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc. Natl Acad. Sci. USA105,17073–17078 (2008).▪▪ Revealed that chemically induced chronic inflammation created local suppression via IDO, and that IDO facilitates tumor development, since IDO1-deficient mice exhibited a robust tumor-resistant phenotype in a two-stage carcinogenesis model.
  Medline CASGoogle Scholar
• 28  Habara-Ohkubo A, Shirahata T, Takikawa O, Yoshida R: Establishment of an antitoxoplasma state by stable expression of mouse indoleamine 2,3-dioxygenase. Infect. Immun.61,1810–1813 (1993).
  Medline CASGoogle Scholar
• 29  Thomas SM, Garrity LF, Brandt CR et al.: IFN-γ-mediated antimicrobial response: Indolemaine 2,3-dioxygenase-deficient mutant host cells no longer inhibit intracellular Chlamydia spp. or Toxoplamagrowth. J. Immunol.150,5529–5534 (1993).
  Medline CASGoogle Scholar
• 30  Bodaghi B, Goureau O, Zipeto D, Laurent L, Virelizier JL, Michelson S:Role of IFN-γ-induced indoleamine 2,3 dioxygenase and inducible nitric oxide syntahse in the replication of human cytomegalovirus in retinal pigmentepithelial cells. J. Immunol.162,957–964 (1999).
  Medline CASGoogle Scholar
• 31  Adams O, Besken K, Oberdorfer C et al.: Role of indoleamine-2,3-dioxygenase in α/β and γ interferon-mediated antiviral effects against herpes simplex virus infections. J. Virol.78,2632–2636 (2004).
  Medline CASGoogle Scholar
• 32  Obojes K, Andres O, Kim KS, Daubener W, Schneider-Schaulies J: Indoleamine 2,3-dioxygenase mediatescell type-specific anti-measles virus activity of γ interferon. J. Virol.79,7768–7776 (2005).
  Medline CASGoogle Scholar
• 33  Bozza S, Fallarino F, Pitzurra L et al.: A crucial role for tryptophan catabolism at the host/Candida albicans interface. J. Immunol.174,2910–2918 (2005).
  Medline CASGoogle Scholar
• 34  van der Sluijs KF, Nijhuis M, Levels JH et al.: Influenza-induced expression of indoleamine 2,3-dioxygenase enhances interleukin-10 production and bacterial outgrowth during secondary pneumococcal pneumonia. J. Infect. Dis.193,214–222 (2006).
  Medline CASGoogle Scholar
• 35  Boasso A, Herbeuval JP, Hardy AW et al.: HIV inhibits CD4⁺ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood109,3351–3359 (2007).▪ Demonstrated that pharmacologic IDO inhibition led to increased peripheral blood mononuclear cell (PBMC)-induced proliferation of human CD4+ T cells, and that increased IDO expression in HIV-infected PBMCs was due to plasmacytoid dendritic cells (pDCs), implicating IDO inhibition as potential immunotherapy for HIV patients.
  Medline CASGoogle Scholar
• 36  Larrea E, Riezu-Boj JI, Gil-Guerrero L et al.: Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection. J. Virol.81,3662–3666 (2007).
  Medline CASGoogle Scholar
• 37  Boasso A, Shearer GM: How does indoleamine 2,3-dioxygenase contribute to HIV-mediated immune dysregulation. Curr. Drug Metab.8,217–223 (2007).
  Medline CASGoogle Scholar
• 38  Potula R, Poluektova L, Knipe B et al.: Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Blood106,2382–2390 (2005).
  Medline CASGoogle Scholar
• 39  Wirleitner B, Neurauter G, Schrocksnadel K, Frick B, Fuchs D: Interferon-g-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr. Med. Chem.10,1581–1591 (2003).
  Medline CASGoogle Scholar
• 40  O’Connor JC, Lawson MA, Andre C et al.: Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol. Psychiatry14,511–522 (2009).
  MedlineGoogle Scholar
• 41  Moreau M, Andre C, O’Connor JC et al.: Inoculation of bacillus Calmette–Guerin to mice induces an acute episode of sickness behavior followed by chronic depressive-like behavior. Brain Behav. Immun.22,1087–1095 (2008).
  Medline CASGoogle Scholar
• 42  Hayashi T, Rao SP, Takabayashi K et al.: Enhancement of innate immunity against Mycobacterium avium infection by immunostimulatory DNA is mediated by indoleamine 2,3-dioxygenase. Infect. Immun.69,6156–6164 (2001).
  Medline CASGoogle Scholar
• 43  Popov A, Abdullah Z, Wickenhauser C et al.: Indoleamine 2,3-dioxygenase-expressing dendritic cells form suppurative granulomas following Listeria monocytogenesinfection. J. Clin. Invest.116,3160–3170 (2006).
  Medline CASGoogle Scholar
• 44  Sakurai K, Zou J, Tschetter J, Ward J, Shearer G: Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J. Neuroimmunol.129,186 (2002).
  Medline CASGoogle Scholar
• 45  Szanto S, Koreny T, Mikecz K et al.: Inhibition of indoleamine 2,3-dioxygenase-mediated tryptophan catabolism accelerates collagen-induced arthritis in mice. Arthritis Res. Ther.9,R50 (2007).
  MedlineGoogle Scholar
• 46  Saxena V, Ondr JK, Magnusen AF, Munn DH, Katz JD: The countervailing actions of myeloid and plasmacytoid dendritic cells control autoimmune diabetes in the nonobese diabetic mouse. J. Immunol.179,5041–5053 (2007).▪▪ Identified pDCs as a DC subset that inhibited murine Type 1 diabetes (T1D) progression, and IDO as an immune modulator of T1D, since pharmacologic inhibition of IDO led to increased insulitis.
  Medline CASGoogle Scholar
• 47  Grohmann U, Fallarino F, Bianchi R et al.: A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice. J. Exp. Med.198,153–160 (2003).
  Medline CASGoogle Scholar
• 48  Fallarino F, Bianchi R, Orabona C et al.: CTLA4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice. J. Exp. Med.200,1051–1062 (2004).
  Medline CASGoogle Scholar
• 49  Ueno A, Cho S, Cheng L et al.: Transient upregulation of indoleamine 2,3-dioxygenase in dendritic cells by human chorionic gonadotropin downregulates autoimmune diabetes. Diabetes56,1686–1693 (2007).
  Medline CASGoogle Scholar
• 50  Sarkar SA, Wong R, Hackl SI et al.: Induction of indoleamine 2,3-dioxygenase by interferon-γ in human islets. Diabetes56,72–79 (2007).
  Medline CASGoogle Scholar
• 51  Matysiak M, Stasiolek M, Orlowski W et al.: Stem cells ameliorate EAE via an indoleamine 2,3-dioxygenase (IDO) mechanism. J. Neuroimmunol.193,12–23 (2008).
  Medline CASGoogle Scholar
• 52  Seo SK, Choi JH, Kim YH et al.: 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat. Med.10,1088–1094 (2004).▪ Introduced 4-1BB as an IDO inducer,and as a potential therapy for rheumatoid arthritis via an IDO-dependent mechanism.
  Medline CASGoogle Scholar
• 53  Zhu L, Ji F, Wang Y et al.: Synovial autoreactive T cells in rheumatoid arthritis resist IDO-mediated inhibition. J. Immunol.177,8226–8233 (2006).
  Medline CASGoogle Scholar
• 54  You S, Belghith M, Cobbold S et al.: Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes54,1415–1422 (2005).
  Medline CASGoogle Scholar
• 55  Xu H, Oriss TB, Fei M et al.: Indoleamine 2,3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammation. Proc. Natl Acad. Sci. USA105,6690–6695 (2008).
  Medline CASGoogle Scholar
• 56  Munn DH, Zhou M, Attwood JT et al.: Prevention of allogeneic fetal rejection by tryptophan catabolism. Science281,1191–1193 (1998).▪▪ First to identify IDO as a T-cell regulatory mechanism by showing that IDO inhibitors allowed maternal T cells to reject allogeneic fetal tissues during mouse pregnancy.
  Medline CASGoogle Scholar
• 57  Mellor AL, Sivakumar J, Chandler P et al.: Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat. Immunol.2,64–68 (2001).
  Medline CASGoogle Scholar
• 58  Miki T, Sun H, Lee Y et al.: Blockade of tryptophan catabolism prevents spontaneous tolerogenicity of liver allografts. Transplant. Proc.33,129–130 (2001).
  Medline CASGoogle Scholar
• 59  Guillonneau C, Hill M, Hubert FX et al.: CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-γ, and indoleamine 2,3-dioxygenase. J. Clin. Invest.117,1096–1106 (2007).
  Medline CASGoogle Scholar
• 60  Reddy P, Sun Y, Toubai T et al.: Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J. Clin. Invest.118,2562–2573 (2008).
  Medline CASGoogle Scholar
• 61  Swanson KA, Zheng Y, Heidler KM, Mizobuchi T, Wilkes DS: CDllc⁺ cells modulate pulmonary immune responses by production of indoleamine 2,3-dioxygenase. Am. J. Respir. Cell Mol. Biol.30,311–318 (2004).
  Medline CASGoogle Scholar
• 62  Liu H, Liu L, Fletcher BS, Visner GA: Sleeping beauty-based gene therapy with indoleamine 2,3-dioxygenase inhibits lung allograft fibrosis. FASEB J.20,2584–2586 (2006).
  Google Scholar
• 63  Yu G, Dai H, Chen J et al.: Gene delivery of indoleamine 2,3-dioxygenase prolongs cardiac allograft survival by shaping the types of T-cell responses. J. Gene Med.10,754–761 (2008).
  Medline CASGoogle Scholar
• 64  Ino K, Yoshida N, Kajiyama H et al.: Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br. J. Cancer95,1555–1561 (2006).
  Medline CASGoogle Scholar
• 65  Brandacher G, Perathoner A, Ladurner R et al.: Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin. Cancer Res.12,1144–1151 (2006).
  Medline CASGoogle Scholar
• 66  Okamoto A, Nikaido T, Ochiai K et al.: Indoleamine 2,3-dioxygenase servesas a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin. Cancer Res.11,6030–6039 (2005).
  Medline CASGoogle Scholar
• 67  Takao M, Okamoto A, Nikaido T et al.: Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer. Oncol. Rep.17,1333–1339 (2007).
  Medline CASGoogle Scholar
• 68  Pan K, Wang H, Chen MS et al.: Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J. Cancer Res. Clin. Oncol.134,1247–1253 (2008).
  Medline CASGoogle Scholar
• 69  Brandacher G, Cakar F, Winkler C et al.: Non-invasive monitoring of kidney allograft rejection through IDO metabolism evaluation. Kidney Int.71,60–67 (2007).
  Medline CASGoogle Scholar
• 70  Widner B, Sepp N, Kowald E et al.: Enhanced tryptophan degradation in systemic lupus erythematosus. Immunobiology201,621–630 (2000).
  Medline CASGoogle Scholar
• 71  Pertovaara M, Raitala A, Uusitalo H et al.: Mechanisms dependent on tryptophan catabolism regulate immune responses in primary Sjogren’s syndrome. Clin. Exp. Immunol.142,155–161 (2005).
  Medline CASGoogle Scholar
• 72  Pertovaara M, Hasan T, Raitala A et al.: Indoleamine 2,3-dioxygenase activity is increased in patients with systemic lupus erythematosus and predicts disease activation in the sunny season. Clin. Exp. Immunol.150,274–278 (2007).
  Medline CASGoogle Scholar
• 73  Munn DH, Sharma MD, Lee JR et al.: Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science297,1867–1870 (2002).
  Medline CASGoogle Scholar
• 74  Fallarino F, Vacca C, Orabona C et al.: Functional expression of indoleamine 2,3-dioxygenase by murine CD8a(⁺) dendritic cells. Int. Immunol.14,65–68 (2002).
  Medline CASGoogle Scholar
• 75  Mellor AL, Chandler PR, Baban B et al.: Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int. Immunol.16,1391–1401 (2004).
  Medline CASGoogle Scholar
• 76  Baban B, Hansen AM, Chandler PR et al.: A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. Int. Immunol.17,909–919 (2005).
  Medline CASGoogle Scholar
• 77  Mellor AL, Baban B, Chandler PR et al.: Cutting edge: CpG oligonucleotides induce splenic CD19⁺ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN type 1 signaling. J. Immunol.175,5601–5605 (2005).
  Medline CASGoogle Scholar
• 78  Manlapat AM, Kahler DJ, Chandler PR, Munn DH, Mellor AL: Cell autonomous control of interferon type I expression by indoleamine 2,3-dioxygenase in regulatory CD19⁺ dendritic cells. Eur. J. Immunol.37,1064–1071 (2007).
  Medline CASGoogle Scholar
• 79  Fallarino F, Gizzi S, Mosci P, Grohmann U, Puccetti P: Tryptophan catabolism in IDO⁺ plasmacytoid dendritic cells. Curr. Drug Metab.8,209–216 (2007).
  Medline CASGoogle Scholar
• 80  Belladonna ML, Volpi C, Bianchi R et al.: Cutting edge: Autocrine TGF-β sustains default tolerogenesis by IDO-competent dendritic cells. J. Immunol.181,5194–5198 (2008).
  Medline CASGoogle Scholar
• 81  Orabona C, Belladonna ML, Vacca C et al.: Cutting edge: silencing suppressor of cytokine signaling 3 expression in dendritic cells turns CD28-Ig from immune adjuvant to suppressant. J. Immunol.174,6582–6586 (2005).
  Medline CASGoogle Scholar
• 82  Orabona C, Tomasello E, Fallarino F et al.: Enhanced tryptophan catabolismin the absence of the molecular adapter DAP12. Eur. J. Immunol.35,3111–3118 (2005).
  Medline CASGoogle Scholar
• 83  Fallarino F, Orabona C, Vacca C et al.: Ligand and cytokine dependence of the immunosuppressive pathway of tryptophan catabolism in plasmacytoid dendritic cells. Int. Immunol.17,1429–1438 (2005).
  Medline CASGoogle Scholar
• 84  Orabona C, Pallotta MT, Volpi C et al.: SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc. Natl Acad. Sci. USA105,20828–20833 (2008).
  Medline CASGoogle Scholar
• 85  Orabona C, Puccetti P, Vacca C et al.: Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood107,2846–2854 (2006).▪ Identified DAP12 and IRF-8 as signal mechanisms that regulate IDO functional competence in dendritic cells (DCs).
  Medline CASGoogle Scholar
• 86  Ron D: Translational control in the endoplasmic reticulum stress response. J. Clin. Invest.110,1383–1388 (2002).
  Medline CASGoogle Scholar
• 87  Harding HP, Zhang Y, Zeng H et al.: An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol. Cell11,619–633 (2003).
  Medline CASGoogle Scholar
• 88  Gajewski TF, Meng Y, Blank C et al.: Immune resistance orchestrated by the tumor microenvironment. Immunol. Rev.213,131–145 (2006).
  Medline CASGoogle Scholar
• 89  Fallarino F, Grohmann U, Vacca C et al.: T cell apoptosis by tryptophan catabolism. Cell Death Differ.9,1069–1077 (2002).
  Medline CASGoogle Scholar
• 90  Fallarino F, Grohmann U, Hwang KW et al.: Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol.4,1206–1212 (2003).
  Medline CASGoogle Scholar
• 91  Fallarino F, Grohmann U, You S et al.: The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor {z}-chain and induce a regulatory phenotype in naiveT cells. J. Immunol.176,6752–6761 (2006).
  Medline CASGoogle Scholar
• 92  Hill M, Tanguy-Royer S, Royer P et al.: IDO expands human CD4⁺CD25high regulatory T cells by promoting maturation of LPS-treated dendritic cells. Eur. J. Immunol.37,3054–3062 (2007).
  Medline CASGoogle Scholar
• 93  Chen Z, O’Shea JJ: Th17 cells: a new fate for differentiating helper T cells. Immunol. Res.41,87–102 (2008).
  Medline CASGoogle Scholar
• 94  Grohmann U, Fallarino F, Bianchi R et al.: IL-6 inhibits the tolerogenic function of CD8α(⁺) dendritic cells expressing indoleamine 2,3-dioxygenase. J. Immunol.167,708–714 (2001).
  Medline CASGoogle Scholar
• 95  Lee GK, Park HJ, Macleod M et al.: Tryptophan deprivation sensitizes activatedT cells to apoptosis prior to cell division. Immunology107,1–9 (2002).
  MedlineGoogle Scholar
• 96  Munn DH, Sharma MD, Baban B et al.: GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity22,1–10 (2005).
  Google Scholar
• 97  Sharma MD, Baban B, Chandler PR et al.: Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes activate mature Tregs via indoleamine 2,3-dioxygenase. J. Clin. Invest.117,1–13 (2007).▪ Revealed that pDCs expressing IDO directly activated Tregs to create local suppression in tumor-draining lymph nodes that was dependent on the PD-1/PD-L pathway.
  Google Scholar
• 98  Naugler WE, Sakurai T, Kim S et al.: Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science317,121–124 (2007).
  Medline CASGoogle Scholar
• 99  Swann JB, Vesely MD, Silva A et al.: Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc. Natl Acad. Sci. USA105,652–656 (2008).
  Medline CASGoogle Scholar
• 100  Cady SG, Sono M: 1-methyl-dl-tryptophan, β-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and β-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch. Biochem. Biophys.291,326–333 (1991).
  Medline CASGoogle Scholar
• 101  Jia L, Schweikart K, Tomaszewski J et al.: Toxicology and pharmacokinetics of 1-methyl-D-tryptophan: absence of toxicity due to saturating absorption. Food Chem. Toxicol.46,203–211 (2008).
  Medline CASGoogle Scholar
• 102  Lob S, Konigsrainer A, Schafer R et al.: Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood111,2152–2154 (2008).
  Medline CASGoogle Scholar
• 103  Lob S, Konigsrainer A, Zieker D et al.: IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol. Immunother.58,153–157 (2009).
  MedlineGoogle Scholar
• 104  Munn DH, Mellor AL, Rossi M, Young JW: Dendritic cells have the option to express IDO-mediated suppression or not. Blood105,2618 (2005).
  Medline CASGoogle Scholar
• 105  Ou X, Cai S, Liu P et al.: Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT. J. Cancer Res. Clin. Oncol.134,525–533 (2008).
  Medline CASGoogle Scholar
• 106  Agaugue S, Perrin-Cocon L, Coutant F, Andre P, Lotteau V: 1-Methyl-tryptophan can interfere with TLR signaling in dendritic cells independently of IDO activity. J. Immunol.177,2061–2071 (2006).
  Medline CASGoogle Scholar
• 107  Banerjee T, Duhadaway JB, Gaspari P et al.: A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene27(20),2851–2857 (2008).
  Medline CASGoogle Scholar
• 108  Basu GD, Tinder TL, Bradley JM et al.: Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J. Immunol.177,2391–2402 (2006).
  Medline CASGoogle Scholar
• 109  Marshall B, Keskin DB, Mellor AL: Regulation of prostaglandin synthesis and cell adhesion by a tryptophan catabolizing enzyme. BMC Biochemistry2,5 (2001).
  Medline CASGoogle Scholar
• 110  Wingender G, Garbi N, Schumak B et al.: Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur. J. Immunol.36,12–20 (2006).
  Medline CASGoogle Scholar
• 111  Guillonneau C, Mintern JD, Hubert FX et al.: Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity. Proc. Natl Acad. Sci. USA106,3330–3335 (2009).
  Medline CASGoogle Scholar
• 112  Tan PH, Beutelspacher SC, Xue SA et al.: Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood105,3824–3832 (2005).
  Medline CASGoogle Scholar
• 113  Grohmann U, Orabona C, Fallarino F et al.: CTLA4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol.3,1097–1101 (2002).▪▪ First to show that DCs could be induced to acquire IDO-dependent T-cell regulatory functions, in this case using soluble cytotoxic T-lymphocyte antigen 4 as a B7 (CD80/86) ligand.
  Medline CASGoogle Scholar
• 114  von Bubnoff D, Matz H, Frahnert C et al.: FcepsilonRI induces the tryptophan degradation pathway involved in regulating T cell responses. J. Immunol.169,1810–1816 (2002).
  Medline CASGoogle Scholar
• 115  Mellor AL, Baban B, Chandler P et al.: Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J. Immunol.171,1652–1655 (2003).
  Medline CASGoogle Scholar
• 116  Fallarino F, Asselin-Paturel C, Vacca C et al.: Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement. J. Immunol.173,3748–3754 (2004).
  Medline CASGoogle Scholar
• 117  von Bergwelt-Baildon MS, Popov A, Saric T et al.: CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood108,228–237 (2006).
  Medline CASGoogle Scholar
• 118  Grohmann U, Volpi C, Fallarino F et al.: Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat. Med.13,579–586 (2007).
  Medline CASGoogle Scholar
• 119  Furset G, Floisand Y, Sioud M: Impaired expression of indoleamine 2,3-dioxygenase in monocyte-derived dendritic cells in response to Toll-like receptor-7/8 ligands. Immunology123,263–271 (2008).
  Medline CASGoogle Scholar
• 120  Bluestone JA, St Clair EW, Turka LA: CTLA4Ig: bridging the basic immunology with clinical application. Immunity24,233–238 (2006).
  Medline CASGoogle Scholar
• 121  Sacre SM, Drexler SK, Andreakos E et al.: Could toll-like receptors provide a missing link in chronic inflammation in rheumatoid arthritis? Lessons from a study on human rheumatoid tissue. Ann. Rheum. Dis.66(Suppl. 3),iii81–iii6 (2007).
  Medline CASGoogle Scholar
• 122  Munn DH, Sharma MD, Mellor AL: Ligation of B7–1/B7–2 by human CD4(⁺) T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J. Immunol.172,4100–4110 (2004).
  Medline CASGoogle Scholar
• 123  Lenschow DJ, Ho SC, Sattar H et al.: Differential effects of anti-B7–1 and anti-B7–2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med.181,1145–1155 (1995).
  Medline CASGoogle Scholar
• 124  Platten M, Ho PP, Youssef S et al.: Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science310,850–855 (2005).
  Medline CASGoogle Scholar
• 125  Hayashi T, Mo JH, Gong X et al.: 3-hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis. Proc. Natl Acad. Sci. USA104,18619–18624 (2007).
  Medline CASGoogle Scholar
• 126  Amirkhani A, Rajda C, Arvidsson B et al.: Interferon-β affects the tryptophan metabolism in multiple sclerosis patients. Eur. J. Neurol.12,625–631 (2005).
  Medline CASGoogle Scholar